These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 1970200)
1. Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies. Mysliwietz J; Thierfelder S; Hoffmann-Fezer G; Kummer U Transplantation; 1990 Apr; 49(4):749-55. PubMed ID: 1970200 [TBL] [Abstract][Full Text] [Related]
2. Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodies. Kummer U; Thierfelder S; Mysliwietz J Eur J Immunol; 1990 Jan; 20(1):107-12. PubMed ID: 1968387 [TBL] [Abstract][Full Text] [Related]
3. Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement. Thierfelder S; Cobbold S; Kummer U; Waldmann H; Schuh R Exp Hematol; 1985 Oct; 13(9):948-55. PubMed ID: 2864278 [TBL] [Abstract][Full Text] [Related]
4. Antilymphocytic antibodies and marrow transplantation. IX. T-cell depletion in marrow donors with C1q high and low affinity antibodies for suppression of GVHD in fully mismatched mice. Antica M; Hoffmann-Fezer G; Thierfelder S Exp Hematol; 1989 Oct; 17(9):942-7. PubMed ID: 2570711 [TBL] [Abstract][Full Text] [Related]
5. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression. Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571 [TBL] [Abstract][Full Text] [Related]
6. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody. Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630 [TBL] [Abstract][Full Text] [Related]
7. Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T cell monoclonal antibody to the allograft recipients. Knulst AC; Bril-Bazuin C; Benner R Eur J Immunol; 1991 Jan; 21(1):103-7. PubMed ID: 1671355 [TBL] [Abstract][Full Text] [Related]
8. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of various T cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant. OKunewick JP; Kociban DL; Buffo MJ Bone Marrow Transplant; 1990 Mar; 5(3):145-52. PubMed ID: 1691938 [TBL] [Abstract][Full Text] [Related]
11. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. Blazar BR; Taylor PA; Vallera DA J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942 [TBL] [Abstract][Full Text] [Related]
12. Proliferative capacity of senescent lymphocytes. II. Monoclonal antibody stimulation of mucosal and systemic lymphocytes via T cell activation molecules, CD3 epsilon, T cell receptor V beta 8 chain, and phosphatidylinositol-linked anchored receptors THY-1 and LY-6A.2/TAP. Green-Johnson JM; Szewczuk MR Reg Immunol; 1990-1991; 3(6):323-35. PubMed ID: 1983438 [TBL] [Abstract][Full Text] [Related]
13. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease. Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541 [TBL] [Abstract][Full Text] [Related]
14. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. Korngold R; Sprent J J Immunol; 1985 Nov; 135(5):3004-10. PubMed ID: 3876371 [TBL] [Abstract][Full Text] [Related]
15. CD4-/CD8-T cells: amplification in spleens of mice following in vivo treatment with monoclonal antibody anti-L3T4. Ermak TH; Steger HJ Eur J Immunol; 1988 Feb; 18(2):231-5. PubMed ID: 2894995 [TBL] [Abstract][Full Text] [Related]
16. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127 [TBL] [Abstract][Full Text] [Related]
17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. Drobyski WR; Majewski D; Ozker K; Hanson G J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of murine T cells via the Ly-6C antigen: lack of proliferative response in aberrant T cells from lpr/lpr and gld/gld mice despite high Ly-6C antigen expression. Dumont FJ J Immunol; 1987 Jun; 138(12):4106-13. PubMed ID: 2438334 [TBL] [Abstract][Full Text] [Related]
19. Antilymphocytic antibodies and marrow transplantation. VI. Absence of immunosuppression in vivo after injection of monoclonal antibodies blocking graft-versus-host reactions and humoral antibody formation in vitro. Thierfelder S; Hoffmann-Fezer G; Rodt H; Doxiadis I; Eulitz M; Kummer U Transplantation; 1983 Mar; 35(3):249-54. PubMed ID: 6340277 [TBL] [Abstract][Full Text] [Related]
20. In vivo immunosuppression by pan-T cell antibodies relates to their isotype and to their C1q uptake. Kummer U; Thierfelder S; Hoffmann-Fezer G; Schuh R J Immunol; 1987 Jun; 138(12):4069-74. PubMed ID: 2884259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]